What factors are contributing to the unexpected 30% rise in reported adverse events related to Cerus's INTERCEPT plasma treatment process in European markets this year?

Introduction

The unexpected 30% rise in reported adverse events related to Cerus's INTERCEPT plasma treatment process in European markets this year is a critical issue that demands immediate attention. This analysis will systematically identify, validate, and address the root cause while considering both immediate and long-term implications for our product and users.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might be a seasonal component. Has this increase been consistent throughout the year, or did it spike during specific months?

Why it matters: Seasonal patterns could indicate external factors or usage changes. Expected answer: The increase has been relatively consistent. Impact on approach: If seasonal, we'd focus on usage patterns; if consistent, we'd look more at systemic issues.

• Considering the geographic scope, I'm wondering if this is uniform across all European markets. Are some countries experiencing higher increases than others?

Why it matters: Regional variations could point to local factors or implementation differences. Expected answer: The increase is not uniform, with some countries showing higher rates. Impact on approach: Non-uniform increases would lead us to investigate country-specific factors.

• Given the nature of adverse events, I'm curious about the types of events being reported. Has there been a change in the distribution of event types compared to previous years?

Why it matters: Changes in event types could indicate specific product or process issues. Expected answer: There's been an increase in a particular type of adverse event. Impact on approach: We'd focus our investigation on the factors related to the increased event type.

• Thinking about recent changes, have there been any modifications to the INTERCEPT plasma treatment process or related equipment in the past year?

Why it matters: Recent changes could be directly linked to the increase in adverse events. Expected answer: Some minor updates were made to the treatment process. Impact on approach: We'd scrutinize these updates and their potential impact on safety.